Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers

NCT01535859 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

46

Enrollment

OTHER_GOV

Sponsor class

Conditions

Ovarian Hyperstimulation Syndrome

Interventions

DRUG: Cabergoline
DRUG: Placebo

Sponsor

KK Women's and Children's Hospital